- |||||||||| Phase classification: Project JAY THA Registration Study (clinicaltrials.gov) - Apr 27, 2017
P=N/A, N=100, Completed, Active, not recruiting --> Completed Phase classification: P3 --> P=N/A
- |||||||||| azithromycin / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date, Immunomodulating: Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy (clinicaltrials.gov) - Apr 27, 2017 P1/2, N=0, Withdrawn, Active, not recruiting --> Completed | Trial primary completion date: Dec 2018 --> Mar 2017 N=14 --> 0 | Enrolling by invitation --> Withdrawn | Trial primary completion date: Jul 2012 --> Nov 2014
- |||||||||| Enrollment change: Power Over Pain (POP) Study (clinicaltrials.gov) - Apr 26, 2017
P=N/A, N=177, Active, not recruiting, N=14 --> 0 | Enrolling by invitation --> Withdrawn | Trial primary completion date: Jul 2012 --> Nov 2014 N=144 --> 177
- |||||||||| Trial completion: TC-A Registration Study (clinicaltrials.gov) - Apr 26, 2017
P=N/A, N=162, Completed, Active, not recruiting --> Completed | N=40 --> 26 Active, not recruiting --> Completed
- |||||||||| Trial initiation date: Excia T Cementless EBRA Study (clinicaltrials.gov) - Apr 26, 2017
P=N/A, N=100, Not yet recruiting, Active, not recruiting --> Completed Initiation date: Dec 2016 --> Aug 2017
- |||||||||| Trial primary completion date: Sequencing T-cells in Type I Diabetes Mellitus (clinicaltrials.gov) - Apr 26, 2017
P=N/A, N=40, Active, not recruiting, Initiation date: Dec 2016 --> Aug 2017 Trial primary completion date: Apr 2017 --> Sep 2017
- |||||||||| Orencia (abatacept) / BMS
Trial completion, P4 data: Post-marketing Study Assessing the Long-Term Safety of Abatacept (clinicaltrials.gov) - Apr 25, 2017 P=N/A, N=100000, Completed, Enrolling by invitation --> Completed | Phase classification: P2/3 --> PN/A | N=184 --> 70 | Trial primary completion date: Jan 2014 --> Sep 2015 Active, not recruiting --> Completed
- |||||||||| tibulizumab (ZB-106) / Zura Bio
Trial primary completion date: A Study of LY3090106 in Participants With Sj (clinicaltrials.gov) - Apr 24, 2017 P1, N=32, Recruiting, N=48 --> 21 Trial primary completion date: Sep 2017 --> Mar 2018
- |||||||||| Remicade (infliximab) / J&J
Phase classification: HARIR: Tracking Biologics Along the Silk Road (clinicaltrials.gov) - Apr 21, 2017 P=N/A, N=338, Recruiting, Active, not recruiting --> Completed Phase classification: P4 --> P=N/A
- |||||||||| Trial completion, Enrollment change, Trial primary completion date: Gluten Immunity and Islet Autoimmunity in Type-1 Diabetes (clinicaltrials.gov) - Apr 17, 2017
P=N/A, N=7, Completed, Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2016 --> Sep 2017 Recruiting --> Completed | N=52 --> 7 | Trial primary completion date: Sep 2015 --> Dec 2014
|